Register Login

New Phase 3 Data on Apixaban

Stephen Duff, Co-CEO of Precision BioLogic Inc passed along this announcement. At the American Heart Association meeting, the results of a phase 3 trial indicated that apixaban did not meet the primary efficacy outcome of superiority to enoxaparin (Lovenox) for the endpoint of venous thromboembolism (VTE) and VTE-related death at day 30 in people with acute medical illness. The apixaban arm had a 13 percent lower rate of events than enoxaparin followed by placebo, which favored apixaban but was not statistically significant and thus no clinically directive conclusion can be drawn. The key safety outcome of major bleeding was low in both groups but occurred in more patients treated with apixaban than with enoxaparin (0.47 percent of patients in the apixaban group and 0.19 percent of patients in the enoxaparin group (P=0.04)).

Comments (0)
Anticoagulant Therapy

No comments here.

Leave a Reply